Bico–Forss M: management, 202311– CEO before Vitrolife + AstraZeneca

	Period	2023-11-20
	Organisation	Bico Group AB (publ)
	Group	Bico (Group)
	Organisation 2	Vitrolife AB
	Group	Vitrolife (Group)
	Product	3D bioprinting
	Product 2	laboratory equipment and instruments
	Person	Forss, Maria (Bico Group 202311– CEO before Vitrolife + AstraZeneca)
	Person 2	Gatenholm, Erik (Cellink 201908 CEO + Co-Founder RESIGNED as CEO of Bico 11/23 LEFT Board 5/24)

Bico Group AB. (8/21/23). "Press Release: Maria Forss Is Appointed New President and CEO of Bico Group AB (publ)".

BICO Group AB (publ) announces that Erik Gatenholm, after initiating discussions with the Board of Directors, has decided to step down as President and CEO of BICO Group. Maria Forss has been appointed new President and CEO. Maria Forss will assume office on November 27, 2023, or sooner.

Maria Forss has been appointed new President and CEO and will assume office on November 27, 2023, or sooner. Maria Forss (born 1972) has extensive international experience from leading positions in both medtech and pharma companies, such as Vitrolife and AstraZeneca. The last years within Vitrolife Maria Forss has as the Senior Vice President led the Consumables Business Area and before that she was the Vice President of Business Development and Global Marketing. Maria Forss has successfully developed businesses through the whole value chain and in the whole product life cycle as well as acquisitions and integration of companies.

The Board of Directors has, together with Erik Gatenholm, concluded that the timing is right for a new CEO and President. This discussion was initiated by Erik Gatenholm, and he has together with the board concluded that in the next phase BICO needs a CEO with strong operating skills and experience in scaling a global organization.

“On behalf of the Board of Directors, I would like to welcome Maria Forss. She has profound leadership skills and life science experience, which will secure steadfast focus during BICO’s further development and create shareholder value”, says Rolf Classon, Chairman of the Board, BICO Group AB. “I would also like to thank Erik Gatenholm for his vision and dedication to build a strong life science company. During his tenure the company has evolved into a Group which is built on a market leading commercial portfolio.”

In order to enable a seamless transition, Erik Gatenholm will remain in his current position until Maria Forss assumes as new President and CEO. To secure continuity Erik Gatenholm will, as major shareholder, also remain in his role as board member of BICO.

For more information, please contact:

Rolf Classon, Chairman of the Board, BICO Group AB
Phone: +46 735 46 57 77
E-mail: rc@bico.com

This information is information that BICO Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-08-21 18:45 CEST.

For media inquiries and questions, please contact BICO Investor Relations:
Phone: +46 735 46 57 77
E-mail: ir@bico.com

About BICO

BICO is a leading provider of life science solutions and laboratory automation that enable more efficient development of new treatments with more specificity and less need for animal testing.

The company uses bioconvergence as its operating system, combining advanced technologies with biology to streamline and automate workflows within the pharmaceutical and biopharma industries.

With 32,000+ instruments installed in over 65 countries, BICO products and solutions are found in more than 3,500 laboratories, including the world’s top 20 pharmaceutical companies, and have been cited in over 11,000 publications.

Operating through three business areas – Bioprinting, Biosciences and Bioautomation – the BICO Group strives towards the long-term ambition of enabling the reduction the world’s organ shortage and speeding up drug development to create the future of life-saving treatments.

BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. www.bico.com